The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice.
Transgenic mice bearing the cellular myc oncogene coupled to the immunoglobulin mu or kappa enhancer frequently develop a fatal lymphoma within a few months of birth. Since the tumours represent represent both immature and mature B lymphocytes, constitutive c-myc expression appears to be highly leukaemogenic at several stages of B-cell maturation. These myc mice should aid study of lymphoma development, B-cell ontogeny and immunoglobulin regulation.
D000818:Animals; D001402:B-Lymphocytes / Q000473:pathology; D002454:Cell Differentiation; D004274:DNA, Recombinant; D004742:Enhancer Elements, Genetic; D005786:Gene Expression Regulation; D005796:Genes; D005809:Genes, Regulator; D007136:Immunoglobulins / Q000235:genetics*; D008223:Lymphoma / Q000235:genetics*; D051379:Mice; D009857:Oncogenes; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D011995:Recombination, Genetic; D014158:Transcription, Genetic
D004274:DNA, Recombinant; D007136:Immunoglobulins; D011518:Proto-Oncogene Proteins